These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 2909993)

  • 41. Therapeutic achievements of phosphodiesterase inhibitors and the future.
    Jewitt DE
    Eur Heart J; 1989 Aug; 10 Suppl C():53-9. PubMed ID: 2680498
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Milrinone therapy in catecholamine-dependent critically ill patients with heart failure.
    Siostrzonek P; Koreny M; Delle-Karth G; Haumer M; Koller-Strametz J; Heinz G
    Acta Anaesthesiol Scand; 2000 Apr; 44(4):403-9. PubMed ID: 10757572
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Central and regional vascular hemodynamics of milrinone in experimental heart failure: comparison with captopril and dobutamine].
    Drexler H; Faude F; Winterer H; Wollschläger H; Freudenberg N; Just H
    Z Kardiol; 1987 Aug; 76(8):507-13. PubMed ID: 3314215
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Vitamin C augments the inotropic response to dobutamine in humans with normal left ventricular function.
    Mak S; Newton GE
    Circulation; 2001 Feb; 103(6):826-30. PubMed ID: 11171790
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The central and regional cardiovascular responses to intravenous and intracoronary administration of the phenyldihydropyridine elgodipine in anaesthetized pigs.
    Sassen LM; Soei LK; Koning MM; Verdouw PD
    Br J Pharmacol; 1990 Feb; 99(2):355-63. PubMed ID: 2328400
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Value of the use of milrinone in the treatment of acute crisis in patients with congestive heart failure].
    Gun C; Piegas LS; Bianco AC; Freire RB; Ramos RF; Timerman A
    Arq Bras Cardiol; 1995 Sep; 65(3):255-8. PubMed ID: 8579514
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Outpatient parenteral inotropic therapy for advanced heart failure.
    Young JB; Moen EK
    J Heart Lung Transplant; 2000 Aug; 19(8 Suppl):S49-57. PubMed ID: 11016488
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comparison between mixed venous oxygen saturation and thermodilution cardiac output in monitoring patients with severe heart failure treated with milrinone and dobutamine.
    Nuñez S; Maisel A
    Am Heart J; 1998 Mar; 135(3):383-8. PubMed ID: 9580093
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Beneficial hemodynamic effects of two weeks' milrinone treatment in conscious rats with heart failure.
    Schoemaker RG; Debets JJ; Struyker-Boudier HA; Smits JF
    Eur J Pharmacol; 1990 Jul; 182(3):527-35. PubMed ID: 2226621
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effect of vitamin C and L-NMMA on the inotropic response to dobutamine in patients with heart failure.
    Mak S; Overgaard CB; Newton GE
    Am J Physiol Heart Circ Physiol; 2005 Dec; 289(6):H2424-8. PubMed ID: 16040714
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effects of commonly used inotropes on myocardial function and oxygen consumption under constant ventricular loading conditions.
    DeWitt ES; Black KJ; Thiagarajan RR; DiNardo JA; Colan SD; McGowan FX; Kheir JN
    J Appl Physiol (1985); 2016 Jul; 121(1):7-14. PubMed ID: 27150829
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A Canadian multicentre study of a 48 h infusion of milrinone in patients with severe heart failure.
    Pflugfelder PW; O'Neill BJ; Ogilvie RI; Beanlands DS; Tanser PH; Tihal H; Mizgala HF; Fitchett DH; Kostuk WJ
    Can J Cardiol; 1991; 7(1):5-10. PubMed ID: 2025794
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effects of a novel inotropic agent, BAY y 5959, in conscious dogs: comparison with dobutamine and milrinone.
    Sato N; Uechi M; Asai K; Patrick T; Kudej RK; Vatner SF
    Am J Physiol; 1997 Feb; 272(2 Pt 2):H753-9. PubMed ID: 9124435
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [New inotropic agents in the treatment of congestive heart failure].
    Freitas M
    Rev Port Cardiol; 1993 Nov; 12 Suppl 4():19-28, 7-8. PubMed ID: 7904458
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Acute hemodynamic effects of intravenous sildenafil citrate in congestive heart failure: comparison of phosphodiesterase type-3 and -5 inhibition.
    Botha P; Parry G; Dark JH; Macgowan GA
    J Heart Lung Transplant; 2009 Jul; 28(7):676-82. PubMed ID: 19560695
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Parenteral inotropic support for advanced congestive heart failure.
    Leier CV; Binkley PF
    Prog Cardiovasc Dis; 1998; 41(3):207-24. PubMed ID: 9872607
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Beneficial effects of intermittent home administration of the inotrope/vasodilator milrinone in patients with end-stage congestive heart failure: a preliminary study.
    Cesario D; Clark J; Maisel A
    Am Heart J; 1998 Jan; 135(1):121-9. PubMed ID: 9453531
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Differential therapy of cardiogenic shock with dopamine/milrinone in comparison with dopamine/dobutamine].
    Meissner A; Schmelzle T; Simon R
    Z Kardiol; 1996 Nov; 85(11):839-46. PubMed ID: 9064946
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Milrinone, dobutamine, and nitroprusside: comparative effects on hemodynamics and myocardial energetics in patients with severe congestive heart failure.
    Monrad ES; Baim DS; Smith HS; Lanoue AS
    Circulation; 1986 Mar; 73(3 Pt 2):III168-74. PubMed ID: 3510773
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Hemodynamic and regional blood flow response to milrinone in patients with severe congestive heart failure: a dose-ranging study.
    Fitzpatrick PG; Cinquegrani MP; Vakiener AR; Baggs JG; Biddle TL; Liang CS; Hood WB
    Am Heart J; 1987 Jul; 114(1 Pt 1):97-105. PubMed ID: 3604878
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.